{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2000)
Source:
NDA020715
(2000)
Source URL:
First approved in 2000
Source:
NDA020715
Source URL:
Class:
PROTEIN
Conditions:
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Status:
US Approved Rx
(2000)
Source:
BLA103846
(2000)
Source URL:
First approved in 2000
Source:
BLA103846
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1999)
Source:
BLA103767
(1999)
Source URL:
First approved in 1999
Source:
BLA103767
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761086
(2019)
Source URL:
First approved in 1998
Source:
BLA103772
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103770
(1998)
Source URL:
First approved in 1998
Source:
BLA103770
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA020772
(1998)
Source URL:
First approved in 1998
Source:
BLA020772
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA020898
(1998)
Source URL:
First approved in 1998
Source:
BLA020898
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761100
(2019)
Source URL:
First approved in 1998
Source:
BLA103792
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103764
(1998)
Source URL:
First approved in 1998
Source:
BLA103764
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103795
(1998)
Source URL:
First approved in 1998
Source:
BLA103795
Source URL:
Class:
PROTEIN
